FBIO
Fortress Biotech, Inc.
+0.03 (+1.22%)2.49USD55.8K成交股數205M市值0.9本益比(近四季)3.0股價營收比+14.0%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 18.7M+42% | 16.0M+6% | 17.6M+21% | 16.4M+10% | 13.1M+1% | 15.1M-56% | 14.6M-16% | 14.9M+20% | 13.0M | 34.8M | 17.4M | 12.4M |
| 營業成本 | 6.1M | 6.2M | 5.8M | 4.9M | 4.8M | 4.7M | 4.5M | 5.7M | 6.0M | 6.4M | 7.8M | 6.4M |
| 毛利 | 12.6M+51% | 9.8M-6% | 11.9M+17% | 11.5M+25% | 8.3M+19% | 10.4M-63% | 10.2M+6% | 9.2M+53% | 7.0M | 28.3M | 9.6M | 6.0M |
| 毛利率 | 67.2% | 61.2% | 67.4% | 69.9% | 63.5% | 69.1% | 69.4% | 61.6% | 53.9% | 81.5% | 55.3% | 48.1% |
| 研發費用 | 805K | 540K | 208K | 8.1M | 3.9M | 9.7M | 9.4M | 12.7M | 24.8M | 20.3M | 32.1M | 39.5M |
| 銷售管理費用 | 20.8M | 15.9M | 17.4M | 38.8M | 25.7M | 27.0M | 22.0M | 20.8M | 17.9M | 21.7M | 24.4M | 25.3M |
| 營業利益 | −10.0M-55% | −7.7M-68% | −6.8M-69% | −36.5M+31% | −22.3M-39% | −23.9M+74% | −22.1M-56% | −27.8M-53% | −36.6M | −13.8M | −50.1M | −58.9M |
| 營業利益率 | -53.5% | -48.3% | -38.6% | -222.2% | -169.9% | -158.3% | -151.0% | -186.5% | -280.6% | -39.6% | -288.2% | -473.6% |
| 稅後淨利 | −468K-96% | 110M+83% | 5.9M-145% | 15.5M-241% | −10.6M-31% | 60.2M-1294% | −12.9M-48% | −10.9M-49% | −15.4M | −5.0M | −24.8M | −21.5M |
| 淨利率 | -2.5% | 688.2% | 33.2% | 94.4% | -80.6% | 398.4% | -88.0% | -73.5% | -118.3% | -14.5% | -142.5% | -173.3% |
| 稀釋 EPS | -0.08-83% | 2.82-1863% | 0.11-114% | 0.45-162% | -0.48-54% | -0.16-83% | -0.76-79% | -0.73+248% | -1.04 | -0.94 | -3.65 | -0.21 |
| 稀釋股數 | 31.8M | 38.4M | 33.1M | 29.8M | 26.5M | 20.8M | 19.7M | 18.3M | 17.2M | 7.5M | 7.4M | 102M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 197M | 256M | 86.2M | 74.4M | 91.3M | 57.3M | 58.9M | 76.2M | 83.8M | 72.3M | 78.0M | 152M |
| 應收帳款 | 36.2M | 25.0M | 18.0M | 15.6M | 18.0M | 10.2M | 10.7M | 10.5M | 9.8M | 8.0M | 16.7M | 27.6M |
| 存貨 | 8.2M | 9.3M | 11.8M | 12.9M | 12.5M | 14.4M | 11.8M | 9.7M | 10.6M | 11.0M | 12.2M | 13.3M |
| 總資產 | 317M | 357M | 181M | 160M | 178M | 144M | 127M | 146M | 165M | 151M | 181M | 264M |
| 有息負債 | 35.0M | 37.5M | 47.8M | 50.0M | 56.4M | 58.0M | 52.5M | 67.0M | 61.4M | 45.8M | 55.3M | 92.3M |
| 總負債 | 111M | 155M | 116M | 123M | 146M | 146M | 140M | 160M | 169M | 164M | 197M | 244M |
| 股東權益 | 164M | 162M | 55.9M | 43.9M | 22.3M | 22.7M | 21.2M | 17.9M | 23.0M | 16.7M | 18.5M | 37.8M |
| 負債比 | 34.9% | 43.3% | 64.1% | 76.6% | 81.8% | 101.1% | 110.0% | 110.0% | 102.4% | 108.8% | 108.8% | 92.5% |
| 淨現金(現金 − 有息負債) | 162M | 218M | 38.4M | 24.4M | 35.0M | −699K | 6.4M | 9.2M | 22.4M | 26.5M | 22.7M | 60.2M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 204M | – | – | −19.6M-23% | – | – | – | −25.4M | – | – | −43.2M |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | 0.00 |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | −43.2M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | 0.00 | – | – | 166K | – | – | – | 176K | – | – | 186K |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | -347.7% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 63.3M
| Journey | 61.9M | 97.8% | +10.2% |
|---|---|---|---|
| Avenue Therapeutics Inc | 1.4M | 2.2% | – |
產品／服務2025 年度 · 61.2M
| Qbrexza | 25.0M | 40.8% | -0.4% |
|---|---|---|---|
| Emrosi | 14.7M | 24.1% | – |
| Accutane | 12.9M | 21.0% | -33.6% |
| Foam Franchise Products | 5.9M | 9.6% | -11.9% |
| Other Legacy Product Revenue | 2.7M | 4.5% | -30.9% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 63.3M | +9.7% | 37.0M | 58.5% | -0.07 | – |
| FY2024 | 57.7M | -31.8% | 21.0M | 36.4% | -2.69 | −80.2M |
| FY2023 | 84.5M | +11.6% | 31.0M | 36.7% | -8.47 | −128M |
| FY2022 | 75.7M | +10.1% | −86.6M | -114.3% | -15.97 | −182M |
| FY2021 | 68.8M | +50.9% | −64.7M | -94.1% | -0.79 | −121M |
| FY2020 | 45.6M | +24.5% | −46.5M | -102.0% | -0.65 | −85.6M |
| FY2019 | 36.6M | +36.3% | −40.0M | -109.1% | -0.73 | −97.3M |
| FY2018 | 26.9M | – | −84.1M | -313.0% | -1.94 | −106M |